132 related articles for article (PubMed ID: 24135499)
1. Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity.
Zhang X; Fang X; Gao Z; Chen W; Tao F; Cai P; Yuan H; Shu Y; Xu Q; Sun Y; Gu Y
Anticancer Drugs; 2014 Feb; 25(2):204-11. PubMed ID: 24135499
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
3. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation.
Yuan H; Cai P; Li Q; Wang W; Sun Y; Xu Q; Gu Y
Biomed Pharmacother; 2014 Jul; 68(6):751-6. PubMed ID: 25081318
[TBL] [Abstract][Full Text] [Related]
4. The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.
Rössler J; Monnet Y; Farace F; Opolon P; Daudigeos-Dubus E; Bourredjem A; Vassal G; Geoerger B
Int J Cancer; 2011 Jun; 128(11):2748-58. PubMed ID: 20715103
[TBL] [Abstract][Full Text] [Related]
5. N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.
Ishii-Osai Y; Yamashita T; Tamura Y; Sato N; Ito A; Honda H; Wakamatsu K; Ito S; Nakayama E; Okura M; Jimbow K
J Dermatol Sci; 2012 Jul; 67(1):51-60. PubMed ID: 22622238
[TBL] [Abstract][Full Text] [Related]
6. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
7. Axitinib sensitization of high Single Dose Radiotherapy.
Rao SS; Thompson C; Cheng J; Haimovitz-Friedman A; Powell SN; Fuks Z; Kolesnick RN
Radiother Oncol; 2014 Apr; 111(1):88-93. PubMed ID: 24794795
[TBL] [Abstract][Full Text] [Related]
8. Thujone inhibits lung metastasis induced by B16F-10 melanoma cells in C57BL/6 mice.
Siveen KS; Kuttan G
Can J Physiol Pharmacol; 2011 Oct; 89(10):691-703. PubMed ID: 21905822
[TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
10. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.
Bose A; Lowe DB; Rao A; Storkus WJ
Melanoma Res; 2012 Jun; 22(3):236-43. PubMed ID: 22504156
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic effects of axitinib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on laser-induced choroidal neovascularization in mice.
Kang S; Roh CR; Cho WK; Park KC; Yang KJ; Choi HS; Kim SH; Roh YJ
Curr Eye Res; 2013 Jan; 38(1):119-27. PubMed ID: 23013553
[TBL] [Abstract][Full Text] [Related]
12. Licochalcone E present in licorice suppresses lung metastasis in the 4T1 mammary orthotopic cancer model.
Kwon SJ; Park SY; Kwon GT; Lee KW; Kang YH; Choi MS; Yun JW; Jeon JH; Jun JG; Park JH
Cancer Prev Res (Phila); 2013 Jun; 6(6):603-13. PubMed ID: 23625311
[TBL] [Abstract][Full Text] [Related]
13. Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo.
He Q; Gao J; Ge S; Wang T; Li Y; Peng Z; Li Y; Shen L
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1575-83. PubMed ID: 24804814
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
15. Silymarin suppressed lung cancer growth in mice via inhibiting myeloid-derived suppressor cells.
Wu T; Liu W; Guo W; Zhu X
Biomed Pharmacother; 2016 Jul; 81():460-467. PubMed ID: 27261626
[TBL] [Abstract][Full Text] [Related]
16. 17β-estradiol-linked nitro-L-arginine as simultaneous inducer of apoptosis in melanoma and tumor-angiogenic vascular endothelial cells.
Roy S; Reddy BS; Sudhakar G; Kumar JM; Banerjee R
Mol Pharm; 2011 Apr; 8(2):350-9. PubMed ID: 21291219
[TBL] [Abstract][Full Text] [Related]
17. YM-201627: an orally active antitumor agent with selective inhibition of vascular endothelial cell proliferation.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Matsuhisa A; Kudoh M; Shibasaki M
Cancer Lett; 2006 Jul; 238(1):119-27. PubMed ID: 16095812
[TBL] [Abstract][Full Text] [Related]
18. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity.
Chen XY; Zhang W; Zhang W; Wu S; Bi F; Su YJ; Tan XY; Liu JN; Zhang J
Clin Cancer Res; 2006 Oct; 12(19):5834-40. PubMed ID: 17020991
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells.
Wu B; Shen RN; Wang WX; Broxmeyer HE; Lu L
Stem Cells; 1993 Sep; 11(5):412-21. PubMed ID: 8241952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
